Revenue segments as reported by the company.

Service revenue

Product revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Charles River Laboratories

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment consists of the commercial production and sale of research models, research products, and the provision of services related to the maintenance and monitoring of research models and the management of the clients’ research operations. The Discovery and Safety Assessment segment offers integrated drug discovery services directed at the identification, screening, and selection of a lead compound for drug development and offers safety assessment services, including bioanalysis, drug metabolism, pharmacokinetics, toxicology, and pathology. The Manufacturing Support segment consists of Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services, Biologics Solutions, which performs specialized testing of biologics as well as contract development and manufacturing, and Avian Vaccine Services, which supplies specific-pathogen-free chicken eggs and chickens. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Charles River Labs posts record revenue in Q4 2022

Charles River Laboratories delivered a robust performance in Q4 2022, achieving record revenue and exceeding earnings expectations.
While facing challenges such as NHP supply constraints and regulatory issues, the company showcased operational strength and strategic resilience.
Management's focus on addressing headwinds and exploring growth opportunities positions Charles River Laboratories for future success.
Navigating uncertainties in 2023, the company aims to maintain financial stability and drive growth through strategic initiatives.

Charles River Laboratories reports strong Q1 performance amidst NHP challenges

Charles River Laboratories (CRL) had a strong Q1 performance, exceeding expectations and narrowing 2023 guidance amidst NHP supply constraints impact.
Clients continue to choose Charles River for its expertise and solutions, with segments showing growth potential and disciplined capital deployment.
Challenges include NHP supply issues, margin impact concerns, and predicting demand trends, while opportunities lie in rebounding growth and market positioning.
Overall, Charles River remains focused on navigating challenges, leveraging strengths, and capitalizing on growth opportunities in the biopharmaceutical market.

Charles River Labs reports strong Q2 performance amidst market challenges

Charles River Laboratories (CRL) delivered a strong Q2 performance, facing challenges in the DSA segment but expecting improvements in various business segments. The company is capitalizing on its strengths in client mix and global footprint for NHP work, while addressing challenges such as inflationary pressures and aggressive pricing from competitors.

Charles River Labs surpasses Q3 expectations amidst client caution

Charles River Laboratories delivered a solid performance in Q3, exceeding earnings expectations despite challenges from cautious client spending and margin pressures. Strategic initiatives focusing on innovation, compliance, and cost-saving measures are key strengths. Opportunities in successful client support, advanced technology investments, and supply chain enhancements position the company for future growth.

Charles River Labs reports solid 2023 growth, eyes stable 2024

Charles River Laboratories reported solid revenue growth in 2023, with a focus on operational efficiency and revenue enhancement strategies.
While facing challenges like revenue decline in Q4 and fluctuating cancellation rates, the company is optimistic about stable client spending and growth opportunities in 2024.
With a strong performance in the pharma business and strategic acquisitions, Charles River Laboratories is poised for margin improvement and revenue expansion in the coming year.
The company's confidence in pricing strategy, supply stability, and potential for share gains highlight its competitive position and growth prospects.

Charles River Labs reports mixed Q1 results, eyes sequential improvements

Charles River Laboratories navigated mixed Q1 results with strong performances in Manufacturing and RMS segments.
Challenges include slow recovery in Discovery business and potential staff availability constraints in Safety Assessment.
Opportunities lie in sequential improvements in DSA, increased bookings, and careful management of demand environment.

Charles River Labs Q2 revenue declines, focuses on cost efficiency

Charles River Laboratories faces challenges from softening demand trends impacting revenue but is taking actions to streamline costs and optimize operations. Despite revenue decline, the company's manufacturing segment shows growth potential. Opportunities exist in cost savings initiatives and focusing on CDMO business growth.

Charles River Labs beats Q3 expectations, eyes biopharma opportunities

Charles River Laboratories (CRL) delivered strong financial performance in Q3, focusing on cost management and strategic growth initiatives. Despite challenges in the biopharmaceutical sector, opportunities exist in CDMO and Biologics Testing businesses.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Charles River has a positive business outlook, supported by the ongoing trend toward outsourcing in the pharma and biotechnology industry and strengthened capabilities boosted by acquisitions and partnerships.

Charles River Laboratories: A Well-Positioned Early-Stage CRO

Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q2 2019 Results - Earnings Call Transcript

Charles River (CRL) delivered earnings and revenue surprises of 5.16% and -0.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Charles River Laboratories (CRL) Q2 Earnings Beat Estimates

Amedisys

Humana

PRA Health Sciences

Teladoc

Healthcare stocks like HUM, AMED, CRL, TDOC and PRAH are likely to benefit from higher membership and revenues in the second quarter.

Healthcare Stock Q2 Earnings Due on Jul 31: HUM, AMED & More

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Charles River Laboratories (CRL) Q2 Earnings Expected to Decline

Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q1 2019 Results - Earnings Call Transcript

Charles River earnings of $1.40 a share, on an adjusted basis, on $606.4 million in sales beat first-quarter estimates Tuesday.

This Medical Labs Giant Just Topped First-Quarter Expectations

Charles River (CRL) delivered earnings and revenue surprises of 1.45% and 0.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates

Charles River Laboratories (CRL) Q1 Earnings Preview: What's in the Cards?

Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Charles River Laboratories (CRL) Is Up 2.99% in One Week: What You Should Know

Charles River is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

News for Charles River Laboratories Stock (CRL)